Sector News

Right after Takeda deal, Denali medical director heads to rival Alkahest

January 24, 2018
Life sciences

Hard on the heels of a big IPO and a lucrative deal with Takeda, one of Denali’s top executives is leaving the company to join anti-aging startup Alkahest.

Jonas Hannestad, M.D., Ph.D.—who is also adjunct assistant professor of psychiatry at Yale School of Medicine—is taking up the role of senior medical director at Alkahest, moving on from the medical director role he had at South San Francisco-based Denali.

Hannestad’s specialty is neurosciences, including PET imaging in neuroinflammatory and other neurological disorders, which is a good fit for his role at Alkahest heading up clinical programs in Alzheimer’s and Parkinson’s disease. The company is looking at using infusions of plasma from young donors, thought to be rich in soluble factors that it hopes will help counteract nerve cell degeneration.

While still in early-stage development, toward the end of last year Alkahest reported preliminary data in nine patients that suggested improvement in functional activity in patients with mild-to-moderate Alzheimer’s.

Hannestad is leaving Denali at a time when its star seems to be in the ascendency. His departure comes shortly after the biotech signed a partnership deal with Takeda, including $150 million in upfront cash and stock, that is focusing on three candidates for neurodegenerative diseases based on Denali’s ATV delivery tech that ushers drugs across the blood-brain barrier.

That deal came shortly after it raised $250 million in an IPO last month, although as it stands just one of its programs—LRRK2 inhibitor DNL201 for Parkinson’s—has reached the clinical trials stage.

Hannestad is one of two new hires for Alkahest along with Karl Trass, who joins the San Carlos biotech from Tobira Therapeutics where he was vice president, regulatory affairs prior to Tobira’s acquisition by Allergan in 2016.

Alkahest chief operating officer Helen Jenkins said the new appointments will expand the development team at the company “as we work to bring innovative medicines to patients with Alzheimer’s disease, Parkinson’s disease and other serious diseases of aging.”

By Phil Taylor

Source: Fierce Biotech

comments closed

Related News

March 19, 2023

Ferring Pharmaceuticals’ 1st in class C.diff Treatment, Rebyota, experiences a positive early launch ahead of potential competition

Life sciences

With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.

March 19, 2023

UCB enters drug discovery collaboration with Aitia

Life sciences

Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.

March 19, 2023

Novo, Medtronic add $25M in fuel to FIRE1 and its heart failure monitoring device

Life sciences

Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.

How can we help you?

We're easy to reach